Perioperative Management of Cardiovascular Medications

Lomivorotov, Vladimir V.; Efremov, Sergey; Abubakirov, Marat; Belletti, Alessandro; Karaskov, Alexander

doi:10.1053/j.jvca.2018.01.018

Cited by 7 publications

(4 citation statements)

References 149 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Significant evidence exists suggesting that perioperative suspension of antithrombotic agents in susceptible individuals can lead to dangerous thrombotic events. 9 , 10 In instances where continuation of antiplatelet/anticoagulation medications may be beneficial for reducing perioperative cardiovascular events, surgeons must consider whether these benefits outweigh the possible bleeding risk posed by these agents. The findings from this study show no significant differences in graft healing, graft success, or hematoma formation in patients receiving anticoagulation or antiplatelet therapy at the time of STSG placement compared with patients who were not, suggesting risk of bleeding and subsequent graft failure attributable to these agents is insignificant.…”

Section: Discussionmentioning

confidence: 99%

“…Several consensus articles, however, have expressed concern about early suspension or cessation of antiplatelet therapy, citing significant risk for cardiovascular morbidity and mortality. 8 , 9 The aim of this study was to assess the impact of perioperative anticoagulation/antiplatelet medications on graft success rates and wound healing outcomes.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Neither Antiplatelet nor Anticoagulant Therapy Increases Graft Failure after Split-thickness Skin Grafting

Walters

Kim

Dekker

et al. 2022

Plastic and Reconstructive Surgery - Global Open

View full text Add to dashboard Cite

Background: Split-thickness skin grafts (STSG) are an effective modality for lower extremity wound coverage. Many patients in the highly comorbid chronic wound population present with cardiovascular disease requiring chronic antiplatelet or anticoagulant therapy, theoretically increasing risk for bleeding complications, donor site morbidity, and poor graft take. Some surgeons advocate temporary cessation of antithrombotic therapy, which may increase cardiovascular risk. The objective of this study was to examine the effects of anticoagulation use on STSG outcomes. Methods: All patients receiving STSGs for lower extremity wounds from 2014 to 2016 at a single institution were retrospectively reviewed. Successful grafts were defined as greater than 99.5% wound coverage. Patients were divided into two groups: anticoagulation/antiplatelet or no anticoagulation/antiplatelet. Continuous variables were described by means and SDs and analyzed using student’s t-test. Categorical variables were described by frequencies and percentages and analyzed using Chi-square or Fisher exact tests as appropriate. Results: In total, 231 wounds were identified among 189 patients; 124 patients were receiving at least one antiplatelet/anticoagulant at time of grafting. Three hematomas were reported during 30 days of follow-up; there was no significant difference between groups (P > 0.05). Anticoagulation/antiplatelet therapy in the perioperative period had no significant impact on STSG take and overall healing. Conclusions: The findings from this study demonstrate that administration of anticoagulant/antiplatelet agents in the perioperative period does not increase the risk of skin graft failure. Based on these findings, STSG can be performed without cessation of anticoagulation or antiplatelet therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Neither Antiplatelet nor Anticoagulant Therapy Increases Graft Failure after Split-thickness Skin Grafting

Walters

Kim

Dekker

et al. 2022

Plastic and Reconstructive Surgery - Global Open

View full text Add to dashboard Cite

show abstract

“…Preoperatively, class III antiarrhythmic agents should be continued, as there is a risk of arrhythmia recurrence when these agents are abruptly discontinued. 5,[80][81][82] Postoperatively, these agents should be reinitiated as soon as feasible.…”

Section: Class III Antiarrhythmic Agents (Potassium-channel Blockers)mentioning

confidence: 99%

Preoperative Management of Cardiovascular Medications: A Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement

Sahai

Balonov

Bentov

et al. 2022

Mayo Clinic Proceedings

View full text Add to dashboard Cite

“…On the other hand, renin-angiotensin blockade is associated with increased mortality in patients undergoing noncardiac surgery. 10 Because there is no strong evidence that supports the perioperative use of these drugs, this would become a major limitation of future trials.…”

mentioning

confidence: 99%

Regional Versus General Anesthesia for Carotid Endarterectomy: Do We Need Another Randomized Trial?

Lomivorotov

Shmyrev

Непомнящих

2019

Journal of Cardiothoracic and Vascular Anesthesia

Self Cite

View full text Add to dashboard Cite

Perioperative Management of Cardiovascular Medications

Cited by 7 publications

References 149 publications

Neither Antiplatelet nor Anticoagulant Therapy Increases Graft Failure after Split-thickness Skin Grafting

Neither Antiplatelet nor Anticoagulant Therapy Increases Graft Failure after Split-thickness Skin Grafting

Preoperative Management of Cardiovascular Medications: A Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement

Regional Versus General Anesthesia for Carotid Endarterectomy: Do We Need Another Randomized Trial?

Contact Info

Product

Resources

About